Nordic Life Science
Nordic Life Science
The latest business news
RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII) to develop treatments of degenerative eye disorders The funding will be used to prepare its lead drug RP001 for a clinical
The company has submitted a new patent application for its diabetes project and reports promising experimental data. Follicum has identified a new class of peptides that increase insulin secretion in
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum
AstraZeneca and Merck & Co have announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Priority Review for the use of
SunRegen Healthcare was announced as the winner of the BIO-Europe 2018 Startup Slam competition, held in Copenhagen. Eight life sciences startups pitched at this popular session, sponsored and co-hosted by
The company announces that the FDA has accepted its sevuparin IND for the treatment of SCD. “The FDA’s decision to accept the IND application for the development of sevuparin in
Drug & Device development
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney
The company announces that the dosing of patients in its first trial PPCT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is
Swedish ExpreS2ion Biotech Holding AB announces that The Jenner Institute of the University of Oxford have presented positive results from its Phase I/IIa clinical studies with their RH5.1 bloodstage malaria
The first patient has been dosed in a Phase 2 study evaluating the company’s cancer immunotherapy, BN-Brachyury, and radiation in patients with advanced chordoma. Chordoma is a rare cancer that
The company announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). Rituximab is
The new trial evaluates the combination therapy of CV301 and durvalumab in metastatic colorectal and pancreatic cancers. The first patient has been dosed in a clinical study evaluating CV301, the
Thomas Andersson is the new Senior Advisor for Business Development at Oslo Cancer Cluster and Oslo Cancer Cluster Incubator. Thomas holds a Ph.D. in Physical Chemistry from Lund University in Sweden
Latest news
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney
The company announces that the dosing of patients in its first trial PPCT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is
Swedish ExpreS2ion Biotech Holding AB announces that The Jenner Institute of the University of Oxford have presented positive results from its Phase I/IIa clinical studies with their RH5.1 bloodstage malaria
The first patient has been dosed in a Phase 2 study evaluating the company’s cancer immunotherapy, BN-Brachyury, and radiation in patients with advanced chordoma. Chordoma is a rare cancer that
The company announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL). Rituximab is
The new trial evaluates the combination therapy of CV301 and durvalumab in metastatic colorectal and pancreatic cancers. The first patient has been dosed in a clinical study evaluating CV301, the
The company has announced that DAYBREAKi, the first phase III study for Lu AF35700, an investigational, novel, once-daily, oral antipsychotic drug candidate for the potential treatment of treatment-resistant schizophrenia (TRS), did
The company has announced results from its phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken
The company has presented results from its HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea,
The latest research news from the Nordic region
Science Article
A large research study shows that the appendix acts as a reservoir for disease-associated proteins and appendectomy lowers the risk of developing Parkinson’s disease. The study involved scientists from Van
A new structure in human cells, called reticular adhesions, has been discovered by researchers at Karolinska Institutet in collaboration with colleagues in the UK. The structure is a new type
Fredrik Almqvist, Professor in organic chemistry at Umeå University, and his American research colleague Christina Stallings, receive SEK 24 million from the National Institutes of Health (NIH) for research for
Researchers of organic chemistry and biotechnology from the University of Turku are creating new medical technologies in an Ecosystem coordinated by Orion Corporation. Together with selected university research groups and
Researchers at Karolinska Institutet have examined how effective immunological checkpoint therapy is for individuals with inherited CDKN2A mutation and metastatic melanoma. In recent years, new immunological treatments have appeared that
This week, the Nobel Prizes in Physiology or Medicine, Physics and Chemistry were announced, and all three of them have important life science applications, including cancer immunotherapy, eye operations and the production